(BIM) Biomerieux - Ratings and Ratios

Biomerieux SA (PA:BIM) specializes in developing and marketing advanced in vitro diagnostic solutions, primarily for the detection and monitoring of infectious diseases. The companys products are designed to enhance the accuracy and speed of diagnosis, which is critical for effective patient care and public health management. Its solutions are distributed across the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Among its key offerings are the CHROMID RANGE, a chromogen culture media that provides rapid and selective detection of pathogens; the RAPIDEC CARBA NP biochemical test, which identifies carbapenemase-producing bacteria, crucial for combating antibiotic resistance; and air, surface, and water monitoring systems that ensure hygiene in healthcare settings. The company also offers the BACT/ALERT VIRTUO and BACT/ALERT 3D systems for blood sample culturing, essential for early detection of sepsis.

Biomerieuxs portfolio includes the BIOFIRE multiplex PCR system and the BIOFIRE SPOTFIRE Lowplex PCR point-of-care system, both designed for rapid detection of multiple pathogens. The VITEK MS mass spectrometry system and VITEK 2 automated AST system provide precise identification of pathogens and antibiotic susceptibility, aiding in targeted treatment. The API RANGE and ETEST methods remain reliable for traditional testing needs.

The company also offers the EPISEQ CS solution for whole-genome sequencing, aiding in epidemiologic monitoring and disease outbreak tracking. VIDAS B·R·A·H·M·S PCT is a critical marker for early sepsis detection, vital for timely intervention. The Biomérieux Vision Suite software integrates with these systems, providing actionable data to support clinical decisions.

In the food industry, Biomerieux provides GENE-UP and VERIFLOW for detecting microorganisms, ensuring food safety and regulatory compliance. The company serves clinical, hospital, and industrial laboratories, as well as veterinarians and blood banks. Originally known as B-D Mérieux, the company was founded in 1963 and is headquartered in Marcy-lÉtoile, France, as a subsidiary of Institut Mérieux SA.

Based on the provided data, the 3-month forecast for Biomerieux SA (PA:BIM) considers technical and fundamental factors. The stocks average volume is 131,764, with a last price of 113.00. The SMA trends show a slight dip from 115.13 (20-day) to 114.89 (50-day) and 106.36 (200-day), indicating a potential near-term correction. The ATR of 3.31 suggests moderate volatility.

Fundamentally, the market cap of 13,325.98M EUR reflects a premium valuation. The P/E of 31.04 and forward P/E of 24.15 indicate investor confidence in growth. The P/S ratio of 3.35 and RoE of 12.98 suggest efficient equity use and moderate revenue valuation. Overall, while the stock may face short-term volatility, its strong market position and product portfolio support long-term growth potential.